Edition:
United Kingdom

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

40.17USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$40.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
276,735
52-wk High
$41.52
52-wk Low
$23.34

Select another date:

Tue, May 8 2018

BRIEF-Myriad Genetics Reports Q3 GAAP Earnings Per Share $0.16

* MYRIAD GENETICS REPORTS FISCAL THIRD-QUARTER 2018 FINANCIAL RESULTS

BRIEF-Myriad Receives Pre Market Approval For Its Bracanalysis Diagnostic System In Japan

April 2 Myriad Genetics Inc - ‍Astrazeneca And Merck Are Seeking Approval Of Lynparza In Japan For Treating Patients With Brca :

BRIEF-Myriad Genetics Q2 Adjusted Earnings Per Share $0.31

* MYRIAD GENETICS REPORTS FISCAL SECOND-QUARTER 2018 FINANCIAL RESULTS

UPDATE 1-U.S. FDA approves expanded use of AstraZeneca cancer drug

Jan 12 The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

Select another date: